<DOC>
	<DOCNO>NCT01259089</DOCNO>
	<brief_summary>Hsp90 inhibitor AUY922 erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . This phase I/II trial study side effect best dose Hsp90 inhibitor AUY922 give together erlotinib hydrochloride see well work treat patient stage IIIB-IV non-small cell lung cancer .</brief_summary>
	<brief_title>Hsp90 Inhibitor AUY922 Erlotinib Hydrochloride Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This phase I , dose-escalation study Hsp90 inhibitor AUY922 follow phase II study . Patients receive Hsp90 inhibitor AUY922 IV 1 hour weekly oral erlotinib hydrochloride daily . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>All patient must pathologic evidence advanced lung adenocarcinoma ( stage IIIB stage IV ) confirm histologically/cytologically NU , MSKCC , DFCI EITHER previous RECISTdefined response ( CR PR ) EGFRTKI ( erlotinib gefitinib ) investigational EGFR TK inhibitor OR document mutation EGFR gene ( G719X , exon 19 deletion , L858R , L861Q ) Radiographic progression RECIST treatment erlotinib/gefitinib Received treatment erlotinib/gefitinib throughout one month prior enrollment least six month time Measurable ( RECIST ) indicator lesion previously irradiate Must undergone biopsy development acquire resistance Karnofsky Performance Status &gt; = 70 % OR ECOG/WHO Performance Status 01 Signed inform consent Effective contraception negative serum pregnancy test obtain within two week prior first administration AUY922 premenopausal woman ( ie. , last menstrual period = &lt; 24 month ago ) woman &lt; 2 year onset menopause ; menopause define time fertility cease , woman menstruation &gt; 24 month Total bilirubin = &lt; 1.5 x Upper Limit Normal ( ULN ) AST/SGOT ALT/SGPT = &lt; 3.0 x ULN , = &lt; 5.0 x ULN liver metastasis present Absolute neutrophil count ( ANC ) &gt; = 1.5 x10^9/L Hemoglobin ( Hgb ) &gt; = 9g/dL Platelets ( plts ) &gt; = 100 x 10^9/L Serum creatinine = &lt; 1.5 x ULN 24 hour clearance &gt; = 50 mL/min Symptomatic CNS metastases symptomatic /or require escalate dos steroid Prior treatment HSP90 inhibitor compound Conventional chemotherapy , radiation monoclonal antibody within 4 week ( erlotinib/gefitinib therapy within past 4 week IS allow ) Palliative radiation within 2 week Unresolved diarrhea &gt; = CTCAE grade 2 Pregnant lactate woman Women childbearing potential ( WCBP ) ( i.e . woman able become pregnant ) use doublebarrier method contraception ( abstinence , oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly , surgically sterile ) ; male patient whose partner WCBP use doublebarrier method contraception Acute chronic liver renal disease Other concurrent severe and/or uncontrolled medical condition could cause unacceptable safety risk compromise compliance protocol Major surgery = &lt; 2 week prior randomization recover therapy History ( family history ) long QT syndrome Mean QTc &gt; = 450 msec baseline ECG History clinically manifest ischemic heart disease = &lt; 6 month prior study start History heart failure leave ventricular ( LV ) dysfunction ( LVEF = &lt; 45 % ) MUGA ECG Clinically significant rest bradycardia ( &lt; 50 beat per minute ) Clinically significant ECG abnormality include 1 following : left bundle branch block ( LBBB ) , right bundle branch block ( RBBB ) leave anterior hemiblock ( LAHB ) ; ST segment elevation depression &gt; 1mm , 2nd ( Mobitz II ) , 3rd degree AV block History ventricular tachycardia Other clinically significant heart disease include congestive heart failure ( New York Heart Association class III/IV ) uncontrolled hypertension ( &gt; 160/90 despite intensive medical management ) Patients currently receive treatment medication relative risk prolong QTcF interval switch discontinue alternative drug prior commence AUY922 Known diagnosis HIV infection ( HIV test mandatory ) Patients history another primary malignancy currently clinically significant currently require active intervention Patients receive warfarin ( CoumadinÂ® ) exclude unless = &lt; 2 mg/d , INR &lt; 1.5 Patients know disorder due deficiency bilirubin glucuronidation ( e.g . Gilbert 's syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adenocarcinoma Lung</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
</DOC>